300206.SHE Edan Instruments Inc
- Market cap
- CNY 6.86B
- P/E
- 18.5x
- P/B
- 2.94x
- ROE
- 18.3%
- Dividend yield
- 1.75%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300206.SHE undervalued?
Graham number300206.SHE trades 55.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Edan Instruments Inc fundamental analysis
No fundamental analysis for Edan Instruments Inc yet.
Edan Instruments Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Edan Instruments Inc
Edan Instruments, Inc. engages in the research, development, manufacture, and service of medical electronic equipment and in vitro diagnostic products in China and internationally. The company offers ECG products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as modular and compact patient monitor, vital signs, telemetry and IT products; and obstetrics, pelvic floor rehabilitation, and gynecology…
Full company profileEdan Instruments Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Edan Instruments Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 698M | 843M | 993M | 1.14B | 2.32B | 1.64B | 1.74B | 1.94B | 1.83B | 2.00B | 2.14B |
| Gross Profit | 383M | 469M | 542M | 636M | 1.38B | 915M | 980M | 1.11B | 1.06B | 1.17B | 1.25B |
| Operating Income | 16.2M | 33.5M | 82.0M | 136M | 746M | 245M | 243M | 214M | 165M | 317M | 498M |
| EBITDA | 51.4M | 74.0M | 128M | 167M | 794M | 295M | 294M | 269M | 214M | 372M | 480M |
| Net Income | 26.4M | 43.8M | 92.7M | 132M | 653M | 231M | 233M | 221M | 162M | 306M | 427M |
| EPS | 0.05 | 0.07 | 0.16 | 0.23 | 1.12 | 0.40 | 0.40 | 0.38 | 0.28 | 0.53 | 0.74 |
| Balance Sheet | |||||||||||
| Total Assets | 1.47B | 1.43B | 1.44B | 1.50B | 2.26B | 2.05B | 2.24B | 2.21B | 2.40B | 2.64B | 2.77B |
| Total Liabilities | 242M | 175M | 184M | 198M | 446M | 316M | 384M | 250M | 389M | 450M | 427M |
| Shareholders' Equity | 1.20B | 1.23B | 1.25B | 1.29B | 1.81B | 1.73B | 1.85B | 1.97B | 2.01B | 2.19B | 2.34B |
| Cash & Short-term Investments | 430M | 397M | 278M | 466M | 1.06B | 835M | 957M | 942M | 1.12B | 1.29B | 853M |
| Total Debt | 45.0M | - | - | - | 99.8M | 73.7M | 10.4M | 11.1M | 11.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -44.9M | 114M | 82.3M | 115M | 690M | 237M | 335M | 154M | 371M | 353M | - |
| Capital Expenditure | 108M | 41.6M | 36.6M | 52.9M | 49.1M | 73.6M | 42.4M | 51.1M | 77.7M | 84.7M | 60.3M |
| Free Cash Flow | -153M | 72.4M | 45.8M | 62.4M | 640M | 164M | 293M | 99.9M | 294M | 268M | 252M |
| Ratios | |||||||||||
| ROE | 2.2% | 3.5% | 7.4% | 10.2% | 36.1% | 13.4% | 12.6% | 11.3% | 8.1% | 13.9% | 18.3% |
| ROA | 1.8% | 3.1% | 6.4% | 8.8% | 28.9% | 11.3% | 10.4% | 10.0% | 6.8% | 11.6% | 15.4% |
| Net Profit Margin | 3.8% | 5.2% | 9.3% | 11.6% | 28.2% | 14.1% | 13.4% | 11.4% | 8.8% | 15.3% | 20.0% |
| Debt to Equity | 0.04x | - | - | - | 0.06x | 0.04x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Edan Instruments Inc dividends
- Dividend yield
- 1.75%
- Forward dividend
- 0.31 CNY
- Payout ratio
- 39.4%
- Ex-dividend date
- Apr 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 120M | 0.21 | 39.4% |
| 2024 | CNY 120M | 0.21 | 74.0% |
| 2023 | CNY 120M | 0.21 | 54.2% |
| 2022 | CNY 120M | 0.21 | 51.5% |
| 2021 | CNY 250M | 0.43 | 108.1% |
| 2020 | CNY 100M | 0.17 | 15.3% |
| 2019 | CNY 59.9M | 0.10 | 45.5% |
| 2018 | CNY 49.7M | 0.09 | 53.7% |
| 2017 | CNY 21.3M | 0.04 | 48.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on Jun 1, 2016.
Who owns Edan Instruments Inc
- Insiders 58.23%
- Institutions 3.30%
- Public & others 38.47%
- Shares outstanding 580M
- Free float 254M
Edan Instruments Inc company profile
- Company name
- Edan Instruments Inc
- Ticker
- 300206.SHE
- ISIN
- CNE100001252
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 21, 2011
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,475
- Fiscal year end
- December
- Address
- Jinsha Community, Shenzhen, China, 518122
- Phone
- 86 75 5268 98326
- Website
- edan.com
About Edan Instruments Inc
Edan Instruments, Inc. engages in the research, development, manufacture, and service of medical electronic equipment and in vitro diagnostic products in China and internationally. The company offers ECG products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as modular and compact patient monitor, vital signs, telemetry and IT products; and obstetrics, pelvic floor rehabilitation, and gynecology products. It also provides ultrasound systems that include cart-based color doppler, portable color doppler, and B/W ultrasound systems; and in-vitro diagnostics, which comprise hematology and reagents. In addition, the company offers point-of-care testing systems, including blood gas and chemistry analyzers, disposable arterial blood samplers, and blood gas capillary tubes; and veterinary ultrasound, ECG, laboratory, and monitoring products. Edan Instruments, Inc. was founded in 1995 and is headquartered in Shenzhen, China.
Edan Instruments Inc management
4- Mr. Hao ZhangChairman & President · born 1964
- Mr. Youdong ZuCFO, VP, Secretary, Director & Accounting Supervisor · born 1962
- Mr. Xicheng XieVP & Non-Independent Director · born 1965
- Lin JingyuanExecutive Director of Finance